Successful infliximab therapy in a patient with comorbid spondyloarthritis, primary biliary cirrhosis and generalized morphea

The patient in this report was diagnosed simultaneously with primary biliary cirrhosis (PBC), spondyloarthritis, and generalized morphea and was started on infliximab therapy. In addition to an improvement in clinical symptoms with this therapy, an improvement was also observed in laboratory paramet...

Full description

Saved in:
Bibliographic Details
Published in:Acta clinica belgica (English ed. Online) 2017-10, Vol.72 (5), p.365-368
Main Authors: Resorlu, Hatice, Kılıc, Sevilay, Isık, Selda, Gokmen, Ferhat
Format: Article
Language:English
Subjects:
Antirheumatic Agents - therapeutic use
Bile
Female
Humans
Immunotherapy
Infliximab - therapeutic use
Liver
Liver cirrhosis
Liver Cirrhosis, Biliary - complications
Liver Cirrhosis, Biliary - drug therapy
Middle Aged
Monoclonal antibodies
Scleroderma, Localized - complications
Scleroderma, Localized - drug therapy
Spondylarthritis - complications
Spondylarthritis - drug therapy
TNF inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The patient in this report was diagnosed simultaneously with primary biliary cirrhosis (PBC), spondyloarthritis, and generalized morphea and was started on infliximab therapy. In addition to an improvement in clinical symptoms with this therapy, an improvement was also observed in laboratory parameters such as cholestatic enzymes, C-reactive protein, and erythrocyte sedimentation rate. Infliximab was well tolerated in this 56-year-old patient. However, further studies must be performed in order to clarify the therapeutic role of TNF-α blockers in, PBC and generalized morphea.
ISSN:1784-3286
2295-3337
DOI:10.1080/17843286.2017.1290567